Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
Key Takeaways:
Genecast has filed for a Hong Kong IPO, reporting it lost 1.4 billion yuan over the past three years on big spending for sales and R&D
The cancer molecular diagnostics industry where the company operates is still in its infancy, exposing it to potential risk from future regulation
By Ellie Si
